VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Alphamab Oncology-B (09966.HK) Shares Rise Over 4% as Envafolimab Completes Phase III Enrollment in Resectable NSCLC
Alphamab Oncology-B (09966.HK) Shares Rise Over 4% as Envafolimab Completes Phase III Enrollment in Resectable NSCLC
May 22, 2026 11:31 CST Updated 12:02
Share:
